The biological significance of this mechanism was demonstrated through the substantial clinical benefit observed in Phase 3 testing of the anti-PD-1 monoclonal antibodies nivolumab and pembrolizumab in patients with advanced cancers, where anti-tumor responses to these antibodies correlated with the presence of tumor infiltrating lymphocyte (TIL) activity [14, 15]. The gene discussed is PDCD1; the disease is cancer.